Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men
| Autor: | Joseph Olivieri, Donald Gardenier, Robert Cohen, Jose Lares-Guia, Richie Tran, Lembitu Sorra, Robert Chavez, Punyadech Photangtham, Daniel S. Fierer, Livette Johnson, Paul C. Bellman, Rona Vail, Randy Levine, Patrick Dalton, Rita Chow, Oscar Klein, Alicia Stivala, Donald Kaminsky, Douglas T. Dieterich, Anita Radix, William Shay, Gal Mayer, Susanne Burger, Gabriela Rodriguez-Caprio, Ward Carpenter, Erik Mortensen, Krisczar Bungay, Michel Ng, Ricky Hsu, Susan Weiss, Terry Farrow, Martin Markowitz, Nirupama Somasundaram, Melissa Wiener, William Mandell, Francis Wallach, Michael P. Mullen, Daniel Bowers, John Dellosso, Adrian Demidont, Wouter O. van Seggelen, Eddie Meraz, Eric Leach, Juan Bailey, Stuart Haber, Charles Paolino, Rosanne M. Hijdra, Amisha Malhotra, SI Rapaport, Lawrence Hitzeman, Antonio Urbina, Sneha Jacob, Alison J. Uriel, Andrea D. Branch, Jeffrey C. Kwong, Rodolfo Guadron, Larisa Litvinova, Eileen Donlon, Wen Wang, Lawrence Higgins, Victor Inada, Damaris C. Carriero, Barbara Johnston, Bisher Akil, Stephen Dillon, Shirish Huprikar, David G. Cassagnol, George Psevdos, Irina Linetskaya |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Microbiology (medical) viruses Hepatitis C virus HIV Infections Pilot Projects medicine.disease_cause Antiviral Agents Asymptomatic Telaprevir Men who have sex with men chemistry.chemical_compound Liver disease Pegylated interferon medicine Humans Homosexuality Male business.industry Ribavirin virus diseases Hepatitis C Middle Aged medicine.disease Virology digestive system diseases Infectious Diseases chemistry HIV/AIDS Drug Therapy Combination medicine.symptom business Oligopeptides medicine.drug |
| Zdroj: | Clinical Infectious Diseases. 58:873-879 |
| ISSN: | 1537-6591 1058-4838 |
| Popis: | (See the Editorial Commentary by Zeremski et al on pages 880–2.) Hepatitis C virus (HCV) chronically infects an estimated 5.2 million people in the United States and 170 million people worldwide [1]. However, as most initial (“acute”) infections are completely asymptomatic, newly infected people are rarely identified. The importance of finding these newly HCV-infected people during the acute phase was made clear in the seminal paper by Jaeckel et al [2] that showed a nearly 100% sustained virologic response (SVR) rate using just 24 weeks of interferon alone, an SVR rate many times higher than that of chronically infected patients at that time, and with just half the duration of interferon [3]. We are now faced with an entirely new group of patients who are becoming HCV infected in the international epidemic of sexually transmitted HCV infection among human immunodeficiency virus (HIV)–infected men who have sex with men (MSM). Published cure rates after treatment of acute HCV in these men, using pegylated interferon (peg-IFN) plus ribavirin (RBV) for 24–48 weeks’ duration, are not as good as those of Jaeckel et al [2], ranging from 53% to 83% [4–15], but are clearly better than the 27%–40% success rates in treatment of chronic HCV in HIV-infected men [16, 17]. Still, even with 48 weeks of treatment in many of these studies of acute HCV, fewer than two-thirds of patients achieved SVR, leaving a large proportion of these men uncured, with the possibility of experiencing rapidly advancing liver disease [18–21] and of infecting others and further propagating the epidemic. With the commercial availability of telaprevir (TVR) in the United States, we hypothesized that its potent activity against genotype 1 HCV would allow us to further shorten the treatment period while also improving the SVR rate. We therefore undertook a study of a 12-week treatment course with a combination of TVR, peg-IFN, and RBV in HIV-infected MSM with newly acquired genotype 1 HCV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|